By Doug Macron

Alnylam Pharmaceuticals last week disclosed that long-time partner Novartis has decided not to acquire broad, non-exclusive access to the RNAi drug shop's intellectual property and technologies — a transaction that would have been worth $100 million to Alnylam.

Concurrent with the announcement, Alnylam said that it was cutting between 25 percent and 30 percent of its workforce, which is expected to cost up to $3 million in one-time charges this year but save the company $25 million in 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.